Covista Inc.
Rank #157Capital ReturnCVSA · NYSE · Consumer Defensive
Covista Inc. (CVSA) — Rank #157 by gross profitability (GP/assets 0.37) · ROE 17.4% · Piotroski F-Score 6 / 9.
As-of 2026-09-15 · CIK 0000730464 · all metrics point-in-time as of the filing date.
About
Covista Inc., together with its subsidiaries, provides healthcare education in the United States, Barbados, St.
Show moreShow less
Kitts, and St. Maarten. It operates in three segments: Chamberlain, Walden, and Medical and Veterinary. The company provides degree programs, including bachelor's, master's, and doctoral degrees; and online certificate programs for nursing, health professions, medical, and veterinary postsecondary education, counseling, business, information technology, psychology, public health, social work and human services, public administration and public policy, and criminal justice. It also operates Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. The company was formerly known as Adtalem Global Education Inc. and changed its name to Covista Inc. in February 2026. Covista Inc.
was incorporated in 1987 and is headquartered in Chicago, Illinois.
- Industry
- Education & Training Services
- Sector
- Consumer Defensive
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- June 30
- Website
- covista.com
Price History
Company Snapshot
P/E and reverse DCF are the primary valuation lenses at this stage.
Market Cap
$4.30B
P/E (annual)
17.9
P/S (annual)
2.2
P/B
3.0
P/OCF (annual)
9.1
Shareholder Yield
6.8%
Employees
4,736
Industry
Education & Training Services
Exchange
NYSE
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
2/2 passTerry Smith quality gate
Passes 2/5 Terry Smith thresholdsWhat Growth Is Priced In
Implied revenue growth (10Y)
0.1%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Buyback tailwind: -6.8% — per-share value needs a total required return of -6.8% once share-count change is priced in.
vs. own 6-year median revenue growth: 9.2%
within its own historyCost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
-3.8%
r = 10% (base)
0.1%
r = 12%
3.4%
Net debt / market cap: 5.7%
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / E
Price / diluted EPS
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
P / FCF
Price / free cash flow per share
FCF yield, shareholder yield, and buyback activity are the primary reads at this stage.
Profitability
Gross profitability (GP / assets)
0.37
Primary signal (Novy-Marx).
4th of 8 SIC 8200 peers
Return on equity
17.4%
Gross margin
57.3%
1st of 8 SIC 8200 peers
Revenue growth (YoY)
9.3%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
10.4%
Revenue CAGR (5Y)
16.8%
Earnings CAGR (3Y)
39.2%
FCF CAGR (3Y)
33.3%
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
1.08
7th of 8 SIC 8200 peers (best = lowest)
Current ratio
1.09×
8th of 8 SIC 8200 peers
Quick ratio
0.96×
Net cash
-$256.53M
Cash & equivalents minus total debt.
Recession resistance
Revenue through recessions
Worst single-year YoY revenue decline, 15 years of history
Cash-flow health
Free cash flow
$392.73M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
0.56
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
2.1%
Stock-based comp intensity.
Piotroski F-Score
F-Score
6 / 9
Fundamental-strength score (0-9).